In today's ACT Brief, we examine the FDA's multi-domain transparency priorities, why radiopharmaceutical trials need redesigned infrastructure, and how AI can make enrollment more predictable.
News|Podcasts|April 22, 2026
ACT Brief: Community Engagement for Enrollment, Plausible Mechanism Framework Essentials, and AI Scaling Foundations
Author(s)Andy Studna, Senior Editor
In today's ACT Brief, we explore practical community engagement strategies that drive representative enrollment, how sponsors should structure development plans around the plausible mechanism framework, and the organizational prerequisites for scaling AI effectively in drug development.
This is the Applied Clinical Trials Brief—your fast track to the latest insights shaping clinical operations and drug development.
- In part two of his video
interview , Del Smith, PhD, CEO and co-founder of Acclinate, outlined what a practical, sustained community engagement framework looks like and how sponsors can translate that investment into faster, more efficient, and more representative enrollment by building genuine partnerships rather than treating engagement as a recruitment tactic. - In a new
Q&A rounding out the video interview series, Mwango Kashoki, MD, MPH, SVP and global head of regulatory strategy at Parexel, broke down the FDA's plausible mechanism framework. First-in-human studies can now serve as pivotal trials for individualized therapies, requiring sponsors to plan early FDA engagement, invest in robust non-clinical programs, qualify biomarkers, and structure adaptive trial designs from the outset to support approval. - In a new contributed
article from Pharmaceutical Executive, scaling AI in pharma requires more than algorithms. Organizations must define measurable patient-centered outcomes before deployment, build rigorous data foundations across siloed systems, and maintain human oversight at key decision points. Without cross-functional alignment on what success means, AI deployments risk optimizing computationally strong candidates with poor access or regulatory feasibility.
That's all for today's ACT Brief. Join us tomorrow for more updates shaping clinical operations and drug development. Thanks for listening.
Related to this article
In today's ACT Brief, we examine FDA input sought on early-phase ibogaine protocols, why mixed outsourcing models spread faster than oversight infrastructure, and a major partnership for a rare kidney disease treatment.
In today's ACT Brief, we examine practical guidance for clinical operations teams beginning AI adoption, how hierarchical endpoints better reflect treatment benefit, and why early-stage program failures signal smarter pipeline management.
In today's ACT Brief, we examine how AI enables sponsors to pressure-test protocols before enrollment, HHS's multi-initiative effort to accelerate trial design and execution, and FDA approval expanding heart disease therapy to adolescents.
In today's ACT Brief, we examine AI's role as trial design advisor with human leadership, how to govern autonomous agents in regulated operations, and real-world outcomes from switching to oral weight-loss therapy.
In today's ACT Brief, we examine how data drives honest enrollment assumptions, why RWE infrastructure lags ambition, and the disconnect between FDA rulemaking and enforcement on compounded therapies.
In today's ACT Brief, we examine what AI simulations surface in trial design, how RBQM delivers measurable financial returns, and three new FDA-approved treatments across hair loss, movement disorder, and bone disease.
In today's ACT Brief, we examine how AI is surfacing endpoint options beyond traditional design thinking, why sponsor oversight of outsourced work often fails on inspection despite being robust in practice, and a new combination drug for advanced kidney cancer.
Trending on Applied Clinical Trials Online
1
FDA Releases Transparency Roadmap Outlining Disclosure Priorities Across Drug Development and Regulatory Review
2
FDA Seeks Public Input on Early-Phase Clinical Trial Design for Ibogaine
3
Beyond the Molecule: Why Radiopharmaceutical Trials Require a New Operating Model
4
Operation TrialBlazer Leveraging New and Anticipated US Policy Changes in Early Development
5